Jose de la Cerda
Medical · San Antonio, TXNPI 1801103205
Payments from drug & device makers
What this record shows
17 manufacturers reported payments, led by Johnson & Johnson at 54.0% of the total. Reporting peaked in 2023 at $1,093 and has fallen 59.4% since, to $443 in 2025.
Across 44 payments — averaging $44.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Amgen$261
- Novartis$130
- AbbVie$106
- Pfizer$99
- Myovant Sciences Inc.$45
- plus $264 from 11 others
Across 22 payments — averaging $48,265 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
What the payments were for
- Consulting fees$1,01051%
- Food & beverage$95949%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $1,063 |
| Amgen | 15 | $261 |
| Novartis | 6 | $130 |
| AbbVie | 1 | $106 |
| Pfizer | 4 | $99 |
| Myovant Sciences Inc. | 2 | $45 |
| Bayer | 2 | $41 |
| Novo Nordisk | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Vapotherm Inc | 1 | $22 |
| Blue Earth Diagnostics | 1 | $20 |
| GSK | 1 | $19 |
| Merck | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,969 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 15 | $16,211 |
| EliquisApixaban | 22 | $14,945 |
| Rosuvastatin Calcium | 65 | $886 |
| Nifedipine ErNifedipine | 20 | $464 |
| Metoprolol Succinate | 27 | $262 |
| ClopidogrelClopidogrel Bisulfate | 19 | $260 |
| Amlodipine Besylate | 47 | $223 |
| Carvedilol | 28 | $131 |
| Lisinopril | 27 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $99 | $14,94522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,490 medical providers in Texas.
Other medical in San Antonio
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
- John KodoskySan Antonio$58K
- Amanda MillerSan Antonio$27K
- Felipe GalvanSan Antonio$26K
- Ledyenska BallesterosSan Antonio$22K
- Daniella ArellanoSan Antonio$15K
- Robert SchonhoffSan Antonio$14K
- Tanya GainesSan Antonio$14K
- Ivanna SaucedoSan Antonio$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.